non-small cell lung cancer

J&J Seeks Expanded Use of Lung Cancer Drug Rybrevant
J&J Seeks Expanded Use of Lung Cancer Drug Rybrevant
Yahoo/Zacks.com
JNJ
Rybevant
non-small cell lung cancer
AstraZeneca
Tagrisso
Flag link:
5 Cancer Vaccines to Watch in 2024
5 Cancer Vaccines to Watch in 2024
BioSpace
Merck
Moderna Therapeutics
melanoma
BioNTech
pancreatic cancer
OSE Immunotherapeutics
Transgene
non-small cell lung cancer
Nykode Therapeutics
cervical cancer
Flag link:
AstraZeneca Bid to Expand Imfinzi’s NSCLC Label Hit with Phase III Flop
AstraZeneca Bid to Expand Imfinzi’s NSCLC Label Hit with Phase III Flop
BioSpace
AstraZeneca
Imfinzi
clinical trials
non-small cell lung cancer
Flag link:
Janssen reports data from Phase III trial of lung cancer drug
Janssen reports data from Phase III trial of lung cancer drug
Clinical Trials Arena
JNJ
Janssen
Rybrevant
clinical trials
non-small cell lung cancer
Flag link:
ESMO: AstraZeneca-Daiichi get clarity on patient deaths for Enhertu follow up Dato-DXd, survival data still unclear
ESMO: AstraZeneca-Daiichi get clarity on patient deaths for Enhertu follow up Dato-DXd, survival data still unclear
Fierce Biotech
ESMO
Daiichi Sankyo
AstraZeneca
Enhertu
patient deaths
clinical trials
non-small cell lung cancer
Flag link:
Lung Cancer Takes Center Stage at ESMO Congress 2023 With New Drugs, More Options
Lung Cancer Takes Center Stage at ESMO Congress 2023 With New Drugs, More Options
OBR Oncology
ESMO
non-small cell lung cancer
Roche
Alecensa
AstraZeneca
Tagrisso
JNJ
Rybrevant
Flag link:
Genentech’s Alecensa Reduces the Risk of Disease Recurrence or Death by an Unprecedented 76% in People With ALK-Positive Early-Stage Non-Small Cell Lung Cancer
Genentech’s Alecensa Reduces the Risk of Disease Recurrence or Death by an Unprecedented 76% in People With ALK-Positive Early-Stage Non-Small Cell Lung Cancer
BioSpace
Genentech
Alecensa
ALK inhibitors
non-small cell lung cancer
ESMO
Flag link:
Merck Pushes Keytruda into Perioperative NSCLC Setting with FDA Approval
Merck Pushes Keytruda into Perioperative NSCLC Setting with FDA Approval
BioSpace
Merck
Keytruda
non-small cell lung cancer
Flag link:
AZ’s Tagrisso plus chemo get fast FDA review for lung cancer
AZ’s Tagrisso plus chemo get fast FDA review for lung cancer
Pharmaphorum
AstraZeneca
FDA
Tagrisso
non-small cell lung cancer
EGFR-positive non-small cell lung cancer
Flag link:
Merck's Keytruda hits overall survival goal in early lung cancer as FDA decision nears
Merck's Keytruda hits overall survival goal in early lung cancer as FDA decision nears
Fierce Pharma
Merck
Keytruda
non-small cell lung cancer
Flag link:
FDA Says ‘Systemic Bias’ in Amgen’s Lumakras Trial Ahead of Adcomm Meeting
FDA Says ‘Systemic Bias’ in Amgen’s Lumakras Trial Ahead of Adcomm Meeting
BioSpace
Amgen
Lumakras
non-small cell lung cancer
FDA
Flag link:
Takeda to Withdraw Oncology Drug Exkivity from U.S. Market
Takeda to Withdraw Oncology Drug Exkivity from U.S. Market
Managed Healthcare Executive
Takeda
Exkivity
clinical trials
non-small cell lung cancer
Flag link:
5 FDA decisions to watch in the fourth quarter
5 FDA decisions to watch in the fourth quarter
BioPharma Dive
FDA
Alnylam
Onpattro
ATTR amyloidosis
Vertex Pharmaceuticals
CRISPR Therapeutics
exa-cel
Bluebird Bio
Zynteglo
sickle cell disease
Bristol Myers Squibb
2seventy bio
Abecma
Multiple Myeloma
Amgen
Lumakras
non-small cell lung cancer
Pfizer
estrasimod
ulcerative colitis
Flag link:
J&J's lung cancer therapy succeeds in head-to-head study with AstraZeneca's drug
J&J's lung cancer therapy succeeds in head-to-head study with AstraZeneca's drug
Reuters
JNJ
non-small cell lung cancer
AstraZeneca
Rybrevant
lazertinib
Tagrisso
Flag link:
Latest trial win further supports expanded use of Bristol Myers’ Opdivo in lung cancer
Latest trial win further supports expanded use of Bristol Myers’ Opdivo in lung cancer
BioPharma Dive
Bristol Myers Squibb
Opdivo
non-small cell lung cancer
clinical trials
Flag link:
Could Gilead’s Trodelvy be the next TROP-2 therapy game-changer in NSCLC treatment?
Could Gilead’s Trodelvy be the next TROP-2 therapy game-changer in NSCLC treatment?
Clinical Trials Arena
Gilead Sciences
Trodelvy
TROP-2
non-small cell lung cancer
Flag link:
Merck and Eisai's Keytruda-Lenvima combo chalks up 2 more losses, this time in non-small cell lung cancer
Merck and Eisai's Keytruda-Lenvima combo chalks up 2 more losses, this time in non-small cell lung cancer
Fierce Pharma
Merck
Eisai
Keytruda
Lenvima
melanoma
colorectal cancer
non-small cell lung cancer
Flag link:
AstraZeneca, Daiichi Sankyo show off ADC portfolio with safety top of mind
AstraZeneca, Daiichi Sankyo show off ADC portfolio with safety top of mind
Fierce Biotech
AstraZeneca
Daiichi Sankyo
antibody-drug conjugate
non-small cell lung cancer
Dato-DXd
Flag link:
WCLC: Tagrisso's chemo combo shows edge, but AstraZeneca thinks monotherapy remains king in lung cancer
WCLC: Tagrisso's chemo combo shows edge, but AstraZeneca thinks monotherapy remains king in lung cancer
Fierce Pharma
AstraZeneca
Tagrisso
non-small cell lung cancer
Flag link:
Mirati’s Krazati remains effective in two-year follow-up of NSCLC patients
Mirati’s Krazati remains effective in two-year follow-up of NSCLC patients
Clinical Trials Arena
Mirati Therapeutics
non-small cell lung cancer
Krazati
clinical trials
Flag link:

Pages